ANEUVO

At the INSPIRE Lab at Spaulding Rehabilitation Hospital, groundbreaking research is shaping the future of spinal cord injury (SCI) recovery. Through the INSPIRE Lab, Spaulding is at the forefront of studying transcutaneous spinal stimulation (TSS)—a non-invasive technique that delivers electrical stimulation to spinal networks with the goal of restoring lost motor function. As part of this mission, Spaulding is one of the 14 clinical trial sites for the ASPIRE Study, a collaboration with ANEUVO to evaluate TSS as a potential therapy for improving upper limb function after SCI. The study utilizes ANEUVO’s ExaStim? TSS system, designed to activate spinal neural networks without the need for surgery. This partnership between leading researchers, clinicians, and engineers is an exciting step toward developing new neurorehabilitation therapies that could transform lives. The ASPIRE Clinical Trial represents not just innovation, but a commitment to advancing care and empowering individuals with SCI. Watch to learn more about one study participant's journey with spinal cord injury and participation in ASPIRE. https://lnkd.in/g7m2cmGZ #SpinalCordInjury #NeuroRehabilitation #SpauldingRehabilitation #INSPIRELab #ANEUVO #ASPIREClinicalTrial #TranscutaneousStimulation #MedicalInnovation

Honoring Black History Month: Advancing Equity in Healthcare & Innovation At ANEUVO, we recognize that Black history is deeply intertwined with medical innovation, resilience, and the pursuit of equitable healthcare. From Dr. Charles Drew’s pioneering work in blood preservation to today’s groundbreaking research in neuromodulation, Black scientists, physicians, and advocates have made invaluable contributions to the field of medicine. As we develop neuromodulation therapies for spinal cord injury, we are committed to fostering inclusivity in healthcare innovation. We believe that diverse perspectives drive better patient outcomes, and we strive to advance accessibility and equity in medical technology for all communities. This Black History Month, we celebrate the contributions of Black leaders in science and medicine while reaffirming our dedication to closing healthcare gaps and expanding access to life-changing therapies. Who are some of the Black pioneers in healthcare and innovation that inspire you? Let’s recognize and continue their legacy. #BlackHistoryMonth #HealthcareEquity #InnovationForAll

It’s been a transformative journey since we launched the ASPIRE? clinical trial in February 2023. With ExaStim? at the heart of this study, clinicians across the U.S. have been diligently investigating the safety and efficacy of our neuromodulation device for individuals living with spinal cord injury (SCI). As we near the close of our patient enrollment goal, it's been meaningful to reflect on the incredible individuals who gave their time to participate in this study. Without their willingness to try something new, we couldn't move this impactful work forward. The ASPIRE? study is just the beginning, and we look forward to sharing more milestones on this journey. Caution: Investigational device. Limited by United States law to investigational use.

Happy Holidays from all of us at ANEUVO! As we reflect on this past year, we are filled with gratitude for the incredible people living with spinal cord injuries, clinicians, and partners who inspire our work every day. Together, we’ve made strides in advancing spinal cord injury therapy and pushing the boundaries of innovation in neuromodulation. Wishing you and your loved ones a joyful holiday season and a bright start to the new year!

Congratulations to ONWARD Medical on receiving FDA de novo classification and market authorization for its ARC-EX System. At ANEUVO, we celebrate advancements that bring new hope and innovation to the SCI community. The work of those around us drives ANEUVO to continually elevate and innovate the field of noninvasive neuromodulation with advanced technology designed to deliver personalized, adaptive therapies that further enhance mobility and quality of life for individuals with SCI.

ANEUVO will support the SCI community at the 2024 Steel Assembly Pediatric Spinal Cord Injury and Dysfunction, which will be held from December 13th to 16th in Scottsdale, Arizona. We hope to see you there! #Neuroscience #SCI #SpinalCordInjury #ImprovingLives #ANEUVO #ExaStim #ClinicalTrials #MedicalResearch #HealthcareInnovation

Stories like Anthony Magliari’s remind us of the impact that innovation in spinal cord injury (SCI) therapy can bring. After a 15-year journey of rehabilitation following a motorcycle accident, Anthony has been participating in our ASPIRE? clinical study with ExaStim?, ANEUVO’s Transcutaneous Spinal Stimulation (TSS) device. Designed to activate dormant neural pathways, ExaStim? works alongside rehabilitation to enhance movement and strength in patients living with upper-limb paralysis. While TSS is not a cure, it represents a meaningful advancement in SCI therapy. Thank you to Scripps News's Lindsey Theis for sharing Anthony's story and TRYAbility Neurorecovery Center for allowing a camera crew to spotlight the challenges surrounding SCI recovery. Learn more about our approach to SCI therapy here: https://lnkd.in/gnMz8X7b #SpinalCordInjury #Neuromodulation #ExaStim #ANEUVO #SCIResearch #HealthcareInnovation Caution: Investigational device. Limited by United States law to investigational use.

Today, on Veterans Day, we honor the courage, commitment, and sacrifices of our nation’s veterans. At ANEUVO, we are mindful of the unique challenges many veterans face, especially those with spinal cord injuries. To all veterans, thank you for your service and resilience. We are committed to advancing therapies that can make a positive difference in your lives. #VeteransDay #HonoringService #ANEUVO #ExaStim #SpinalCordInjury #HealthcareInnovation

Next week, ANEUVO will be in Düsseldorf, Germany, from November 11-14, 2024, participating in the MEDICA - Leading International Trade Fair. We're excited to showcase our flagship neuromodulation device, ExaStim?, and look forward to explaining why we believe Transcutaneous Spinal Stimulation is the next frontier for chronic SCI therapy. Please visit our booth, H44, in Hall 10, to learn more. #Neuroscience #SCI #SpinalCordInjury #ImprovingLives #ANEUVO #ExaStim #ClinicalTrials #MedicalResearch #HealthcareInnovation Caution: Investigational device. Limited by United States law to investigational use.

ANEUVO is pleased to announce its attendance at MEDICA - Leading International Trade Fair in Düsseldorf, Germany, November 11-14, 2024! We’re excited to showcase ExaStim?, our flagship neuromodulation device, and share our vision for Transcutaneous Spinal Stimulation as the next frontier in chronic SCI therapy. If you’re attending, stop by our booth, Hall 10, H44, to learn more about how ExaStim is redefining possibilities for those with spinal cord injuries. You can also tap the link below to learn more about ExaStim, including some preliminary results that propelled ANEUVO toward the ASPIRE? clinical trial. In English: https://prez.ly/rRWc Auf Deutsch: https://bit.ly/4fbKbAL #MEDICA2024 #Neuromodulation #SCI #ExaStim #ANEUVO #HealthcareInnovation Caution: Investigational device. Limited by United States law to investigational use.